Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy Study of BETOPTIC S 0.25% and Timolol Gel-forming Solution 0.25% and 0.5% in Pediatric Patients With Glaucoma or Ocular Hypertension

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
INCLUSION:~* Children 5 years old and younger~* require treatment for glaucoma or ocular hypertension~* whose vision is 20/80 or better~* have a cup-to-disc ratio of 0.8 or less~EXCLUSION:~* do not have abnormal fixation~* IOP greater than 36 mm Hg~* significant retinal disease~* penetrating keratoplasty~* severe ocular pathology~* optic atrophy~* eye surgery in the past 30 days~* cardiovascular abnormalities~* hypersensitivity to beta blockers

- Gender: MALE
- Minimum Age: 1 Week
- Maximum Age: 5 Years
- Healthy Volunteers: f

Study Arms:
- Betaxolol (Type: EXPERIMENTAL): Two doses daily for 12 weeks
- TGFS 0.25% (Type: EXPERIMENTAL): Two doses daily for 12 weeks
- TGFS 0.5% (Type: EXPERIMENTAL): Two doses daily for 12 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).